TaiMed Biologics Inc. and Orient EuroPharma Company Limited (OEP) signed an exclusive license agreement for the HIV drug Trogarzo in Taiwan, under which OEP shall pursue regulatory approval, subsequent promotion, and commercial sales of the Product in the above-agreed territory. This agreement grants exclusivity to OEP for the territory of Taiwan. Trogarzo is currently sold primarily in the United States.

In 2024, TaiMed signed exclusive commercialization and distribution license agreements for Trogarzo with AcedrA in the Middle East, North Africa, and WUZHOU in the Hong Kong and Macau regions, respectively. This license agreement with OEP further expands Trogarzo's user base to Taiwan, which will increase the company's operating income in the future and positively impact the company's long-term value. Concrete purpose/objective: The company looks to expand its global reach so more patients can access Trogarzo.